688185 康希诺
交易中 05-27 09:57:44
资讯
新帖
简况
康希诺(688185.SH)：24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)启动I/II期临床试验并完成首例受试者入组
智通财经 · 05-25 16:11
康希诺(688185.SH)：24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)启动I/II期临床试验并完成首例受试者入组
每周股票复盘：康希诺（688185）拟审议未弥补亏损超4.7亿元
证券之星 · 05-24
每周股票复盘：康希诺（688185）拟审议未弥补亏损超4.7亿元
康希诺（688185）披露2025年年度股东会会议资料，5月20日股价下跌2.46%
证券之星 · 05-20
康希诺（688185）披露2025年年度股东会会议资料，5月20日股价下跌2.46%
康希诺：公司将在做好主营业务的基础之上，探索治疗领域的产品
证券日报 · 05-13
康希诺：公司将在做好主营业务的基础之上，探索治疗领域的产品
康希诺跌1.71% 2020年上市募52亿元中信证券保荐
中金财经 · 05-13
康希诺跌1.71% 2020年上市募52亿元中信证券保荐
康希诺最新公告：青少年及成人用百白破疫苗纳入优先审评品种
证券之星 · 05-11
康希诺最新公告：青少年及成人用百白破疫苗纳入优先审评品种
5月11日康希诺涨7.96%，广发科创板两年定开混合基金重仓该股
证券之星 · 05-11
5月11日康希诺涨7.96%，广发科创板两年定开混合基金重仓该股
每周股票复盘：康希诺（688185）H股公众持股量合规
证券之星 · 05-10
每周股票复盘：康希诺（688185）H股公众持股量合规
康希诺（688185）披露将参加2025年度生物制品行业集体业绩说明会暨2026年第一季度业绩说明会，5月6日股价上涨0.13%
证券之星 · 05-06
康希诺（688185）披露将参加2025年度生物制品行业集体业绩说明会暨2026年第一季度业绩说明会，5月6日股价上涨0.13%
康希诺跌4.08% 2020年上市募52亿元中信证券保荐
中金财经 · 04-29
康希诺跌4.08% 2020年上市募52亿元中信证券保荐
图解康希诺一季报：第一季度单季净利润同比下降250.13%
证券之星 · 04-28
图解康希诺一季报：第一季度单季净利润同比下降250.13%
康希诺跌2.53% 2020年上市募52亿元中信证券保荐
中金财经 · 04-20
康希诺跌2.53% 2020年上市募52亿元中信证券保荐
中国首个三组分百白破疫苗获批，康希诺生物成长逻辑跃升
格隆汇 · 04-14
中国首个三组分百白破疫苗获批，康希诺生物成长逻辑跃升
智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧
智通财经 · 04-13
智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧
康希诺最新公告：婴幼儿用吸附无细胞百（三组分）白破联合疫苗获得药品注册证书
证券之星 · 04-12
康希诺最新公告：婴幼儿用吸附无细胞百（三组分）白破联合疫苗获得药品注册证书
每周股票复盘：康希诺（688185）2025年归母净利润同比上升107.36%
证券之星 · 04-05
每周股票复盘：康希诺（688185）2025年归母净利润同比上升107.36%
康希诺：公司已建立起五大全面及完善的研发技术平台
证券日报 · 04-03
康希诺：公司已建立起五大全面及完善的研发技术平台
康希诺：截至目前公司已递交了与婴幼儿用DTcP新药上市申请相关的加强针补充数据
证券日报 · 04-03
康希诺：截至目前公司已递交了与婴幼儿用DTcP新药上市申请相关的加强针补充数据
康希诺：截至2025年12月末母公司不存在未弥补亏损
证券日报 · 04-03
康希诺：截至2025年12月末母公司不存在未弥补亏损
康希诺：根据2025年国内流行病学数据，脑膜炎球菌Y群在整体人群中发病率最高
证券日报 · 04-03
康希诺：根据2025年国内流行病学数据，脑膜炎球菌Y群在整体人群中发病率最高
加载更多
公司概况
公司名称：
康希诺生物股份公司
所属行业：
医药制造业
上市日期：
2020-08-13
主营业务：
康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是疫苗销售、药品生产工艺研究开发业务、技术转移及中间品销售。公司自主研发的“多糖蛋白结合疫苗关键技术及产业化”项目荣获天津市科学技术进步一等奖。
发行价格：
209.71
{"stockData":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":61.15,"timestamp":1779847064000,"preClose":62.36,"halted":0,"volume":649280,"delay":0,"changeRate":-0.0194,"floatShares":113999999,"shares":247000000,"eps":-0.0041,"marketStatus":"交易中","change":-1.21,"latestTime":"05-27 09:57:44","open":62.18,"high":62.18,"low":60.89,"amount":39766600,"amplitude":0.0207,"askPrice":61.15,"askSize":3,"bidPrice":61.1,"bidSize":8,"shortable":0,"etf":0,"ttmEps":-0.0041,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1779852600000},"marketStatusCode":2,"adr":0,"adjPreClose":62.36,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779845400000,1779852600000],[1779858000000,1779865200000]],"highLimit":68.6,"lowLimit":56.12,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":247043801,"isCdr":false,"pbRate":3.13,"roa":"--","roe":"--","epsLYR":0.11,"committee":0.206107,"marketValue":15107000000,"turnoverRate":0.0057,"status":1,"hkstockBrief":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":26.92,"timestamp":1779847037169,"preClose":27.22,"halted":0,"volume":248600,"delay":0,"premium":"-61.89"},"floatMarketCap":6994000000},"requestUrl":"/m/hq/s/688185","defaultTab":"news","newsList":[{"id":"2638535415","title":"康希诺(688185.SH)：24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)启动I/II期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2638535415","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638535415?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:11","pubTimestamp":1779696668,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺(688185.SH)发布公告，公司的24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)(简称“PCV24”)于近日正式启动I/II期临床试验，并完成首例受试者入组。I/II期临床试验为评价PCV24在2月龄(最小6周)及以上人群中接种后安全性与免疫原性的随机、盲法、剂量探索、阳性对照的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺(688185.SH)：24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)启动I/II期临床试验并完成首例受试者入组","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688185","BK0239","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637920375","title":"每周股票复盘：康希诺（688185）拟审议未弥补亏损超4.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637920375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637920375?lang=zh_cn&edition=full","pubTime":"2026-05-24 03:52","pubTimestamp":1779565933,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，康希诺报收于62.4元，较上周的59.98元上涨4.03%。本周，康希诺5月19日盘中最高价报68.48元。康希诺生物股份公司召开2025年年度股东会，审议2025年度董事会工作报告、年度报告及利润分配方案等议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636848150","title":"康希诺（688185）披露2025年年度股东会会议资料，5月20日股价下跌2.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636848150","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636848150?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:48","pubTimestamp":1779270495,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，康希诺报收于63.13元，较前一交易日下跌2.46%，最新总市值为155.96亿元。该股当日开盘64.4元，最高66.47元，最低62.53元，成交额达2.07亿元，换手率为2.82%。康希诺生物股份公司于2026年5月20日披露《2025年年度股东会会议资料》。公告显示，公司拟召开2025年年度股东会，审议2025年度董事会工作报告、年度报告及利润分配方案等议案。公司2025年末合并未分配利润为-471,443,086.47元，实收股本总额三分之一以上为未弥补亏损，故提请股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000034374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635738813","title":"康希诺：公司将在做好主营业务的基础之上，探索治疗领域的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2635738813","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635738813?lang=zh_cn&edition=full","pubTime":"2026-05-13 21:30","pubTimestamp":1778679000,"startTime":"0","endTime":"0","summary":"证券日报网讯5月13日，康希诺在互动平台回答投资者提问时表示，公司将在做好主营业务的基础之上，探索治疗领域的产品，目前正在推进mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发工作，同时会持续布局候选产品线。公司也会根据不同的产品特性、竞争格局及未来价值前景等，拥抱潜在的合作机会及各种可能性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133736241467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635520949","title":"康希诺跌1.71% 2020年上市募52亿元中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2635520949","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635520949?lang=zh_cn&edition=full","pubTime":"2026-05-13 15:56","pubTimestamp":1778658975,"startTime":"0","endTime":"0","summary":"中国经济网北京5月13日讯 康希诺 今日股价下跌，截至收盘，该股报63.80元，跌幅1.71%。该股目前处于破发状态。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海证券。 康希诺首次公开发行股票的发行费用为2.21亿元，其中保荐及承销费用2.05亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260513/32220631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1328615791.USD","IPOS","06030","LU0405327148.USD","LU2289578879.USD","BK0028","LU1720050803.USD","LU1580142542.USD","BK0012","BK0183","LU1655091616.SGD","LU1794554557.SGD","BK1147","BK1521","688185","600030","LU2148510915.USD","BK1516","LU1064130708.USD","LU1255011170.USD","BK1564","LU1997245094.SGD","LU2495084118.USD","BK0188","LU1997245177.USD","BK0276","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","BK0239","BK0196","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634404991","title":"康希诺最新公告：青少年及成人用百白破疫苗纳入优先审评品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404991","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634404991?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:22","pubTimestamp":1778491361,"startTime":"0","endTime":"0","summary":"康希诺(688185.SH)公告称，公司研发的吸附无细胞百(五组分)白破联合疫苗(6岁及以上人群用)已正式纳入国家药监局药品审评中心优先审评品种。该疫苗适用于青少年及成人加强免疫，国内暂无同类获批产品，若成功上市将填补市场空白。公司正准备该产品的上市许可申请递交工作，但后续审评进度及获批时间存在不确定性，对近期业绩无重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100023814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409601","title":"5月11日康希诺涨7.96%，广发科创板两年定开混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409601?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:29","pubTimestamp":1778488190,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日康希诺涨7.96%，收盘报67.7元，换手率5.13%，成交量5.87万手，成交额3.89亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发科创板两年定开混合。广发科创板两年定开混合目前规模为1.21亿元，最新净值1.357，较上一交易日下跌1.65%，近一年上涨61.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634412551","title":"每周股票复盘：康希诺（688185）H股公众持股量合规","url":"https://stock-news.laohu8.com/highlight/detail?id=2634412551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634412551?lang=zh_cn&edition=full","pubTime":"2026-05-10 03:18","pubTimestamp":1778354291,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，康希诺报收于62.71元，较上周的61.51元上涨1.95%。本周，康希诺5月8日盘中最高价报62.99元。康希诺当前最新总市值154.92亿元，在生物制品板块市值排名20/51，在两市A股市值排名1426/5200。公司确认H股类别已符合联交所规定的公众持股量要求。股份期权方面，2025年核心管理层H股购股权计划项下有860,000份期权，本月无变动。2025年A股限制性股票激励计划涉及2,054,600股，本月未新增发行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633189742","title":"康希诺（688185）披露将参加2025年度生物制品行业集体业绩说明会暨2026年第一季度业绩说明会，5月6日股价上涨0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633189742","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633189742?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:33","pubTimestamp":1778063594,"startTime":"0","endTime":"0","summary":"近日，康希诺生物股份公司发布公告称，将于2026年5月13日15:00-17:00参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度生物制品行业集体业绩说明会暨2026年第一季度业绩说明会，通过上证路演中心网络互动方式召开。公司已于2026年3月31日发布2025年年度报告，于2026年4月29日发布2026年第一季度报告。投资者可于2026年5月6日至5月12日16:00前通过上证路演中心网站或公司投资者关系邮箱提问。说明会后可通过上证路演中心查看会议情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631596196","title":"康希诺跌4.08% 2020年上市募52亿元中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2631596196","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631596196?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:42","pubTimestamp":1777455731,"startTime":"0","endTime":"0","summary":"中国经济网北京4月29日讯 康希诺 今日股价下跌，截至收盘，该股报63.30元，跌幅4.08%。该股目前处于破发状态。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海证券。 康希诺首次公开发行股票的发行费用为2.21亿元，其中保荐及承销费用2.05亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260429/32189261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1516","LU2289578879.USD","LU0405327494.USD","BK1521","LU1255011170.USD","IPOS","BK0012","BK0028","688185","LU2495084118.USD","600030","LU1064131003.USD","LU1997245177.USD","BK0188","LU0405327148.USD","BK0183","LU1997245094.SGD","LU1997244956.HKD","LU1720050803.USD","BK0239","LU1781817850.SGD","LU1580142542.USD","LU1328615791.USD","LU1794554557.SGD","LU1655091616.SGD","LU1064130708.USD","BK1147","06030","BK0196","LU2148510915.USD","BK0276","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630705643","title":"图解康希诺一季报：第一季度单季净利润同比下降250.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630705643","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630705643?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:22","pubTimestamp":1777371761,"startTime":"0","endTime":"0","summary":"证券之星消息，康希诺2026年一季报显示，一季度公司主营收入1.9亿元，同比上升38.73%；归母净利润-4042.43万元，同比下降250.13%；扣非净利润-5511.52万元，同比上升0.22%；负债率29.54%，投资收益158.97万元，财务费用925.64万元，毛利率80.94%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"530716c61aaa22cfcffdb04a123fa588","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628674323","title":"康希诺跌2.53% 2020年上市募52亿元中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2628674323","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628674323?lang=zh_cn&edition=full","pubTime":"2026-04-20 16:45","pubTimestamp":1776674703,"startTime":"0","endTime":"0","summary":"中国经济网北京4月20日讯 康希诺 今日股价下跌，截至收盘，该股报69.85元，跌幅2.53%。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海证券。 康希诺首次公开发行股票的发行费用为2.21亿元，其中保荐及承销费用2.05亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260420/32156983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","LU1580142542.USD","LU2495084118.USD","600030","BK0196","LU1794554557.SGD","BK1521","LU0405327148.USD","LU2148510915.USD","06030","LU1064130708.USD","LU1655091616.SGD","LU1997245094.SGD","688185","BK0276","BK0188","LU0405327494.USD","LU2289578879.USD","BK1147","LU1064131003.USD","LU1720050803.USD","BK1516","BK0239","BK1564","IPOS","LU1997245177.USD","BK0183","BK0028","LU1255011170.USD","LU1328615791.USD","LU1997244956.HKD","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627184954","title":"中国首个三组分百白破疫苗获批，康希诺生物成长逻辑跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2627184954","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627184954?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:19","pubTimestamp":1776151191,"startTime":"0","endTime":"0","summary":"盼康欣®的获批，不仅是康希诺生物产品矩阵中又一款重磅新品的落地，深层则是对公司创新技术平台厚度、管线梯度构建能力与商业化体系效率的集中验证。","market":"fut","thumbnail":"https://img2.gelonghui.com/37500-65516e94-e8c5-4b46-9002-7a60e38e1725.jpg?guru_height=853&guru_width=1280&guru_size=129556","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/37500-65516e94-e8c5-4b46-9002-7a60e38e1725.jpg?guru_height=853&guru_width=1280&guru_size=129556"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4407500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159646","BK1191","06185","BK1515","BK1161","BK1574","688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627389104","title":"智通港股早知道 | 香港首批稳定币发行人牌照落地 伊美第三轮谈判双方存在严重分歧","url":"https://stock-news.laohu8.com/highlight/detail?id=2627389104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627389104?lang=zh_cn&edition=full","pubTime":"2026-04-13 07:18","pubTimestamp":1776035912,"startTime":"0","endTime":"0","summary":"牌照于今日生效。伊美第三轮谈判已结束 双方存在严重分歧总台记者当地时间12日获悉，伊朗与美国在伊斯兰堡举行的又一轮会谈已结束。伊朗方面消息称，伊朗与美国代表团在谈判中仍存在一些严重分歧。美伊谈判21小时未达成协议。盛宝银行首席投资策略师 Charu Chanana 表示，美伊谈判无果而终是一次倒退。美英担忧 AI 暴露金融业漏洞Anthropic 发布 AI 模型 Mythos 预览版，美国政府日前召集一批银行高管紧急开会，讨论相关问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7d08dbda469a470286c6f9b045c09156","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300748","C","LU1668664300.SGD","CRCD","LU1861558580.USD","688331","BK1583","LU2328871848.SGD","03317","603083","06088","601869","BK4588","LU2360107671.USD","BK1161","BK1574","LU1791807156.HKD","LU1969619763.USD","BK1596","NVDA","LU0106831901.USD","AMD","LU1861559042.SGD","06680","LU1861217088.USD","ICRC","688185","CRCG","AVGO","BK1556","BK4023","CCUP","CRCO","CRCA","HSBC","00005","BAC","09995","LU1861220207.SGD","BK1500","01729","06185","06166","01773","LUMN","06960","06869","WFC","BK4585","AMZN","BK1228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626717121","title":"康希诺最新公告：婴幼儿用吸附无细胞百（三组分）白破联合疫苗获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626717121","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626717121?lang=zh_cn&edition=full","pubTime":"2026-04-12 15:39","pubTimestamp":1775979589,"startTime":"0","endTime":"0","summary":"康希诺(688185.SH)公告称，公司近日获得国家药监局下发的婴幼儿用吸附无细胞百(三组分)白破联合疫苗(商品名：盼康欣)《药品注册证书》。该疫苗为国内首款上市的组分百白破疫苗，采用每种百日咳抗原单独纯化工艺，确保产品质量稳定。此次获证是公司组分百白破疫苗产品组合中首个获得注册证书的产品，有利于丰富和优化公司商业化产品结构，提升品牌效应。待后续形成销售订单，预计将对公司业绩产生一定积极影响。公司将积极推进产品生产、批签发和上市销售工作，但具体上市时间存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200002767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625191976","title":"每周股票复盘：康希诺（688185）2025年归母净利润同比上升107.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625191976","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625191976?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:18","pubTimestamp":1775330293,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，康希诺报收于67.0元，较上周的68.02元下跌1.5%。本周关注点来自业绩披露要点：康希诺2025年归母净利润2787.27万元，同比上升107.36%。来自公司公告汇总：康希诺H股与A股已发行股份在2026年3月内无变动。股本股东变化截至2026年2月28日，康希诺股东户数为1.75万户，较2025年12月31日增加551.0户，增幅3.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624668563","title":"康希诺：公司已建立起五大全面及完善的研发技术平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668563","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624668563?lang=zh_cn&edition=full","pubTime":"2026-04-03 21:28","pubTimestamp":1775222880,"startTime":"0","endTime":"0","summary":"证券日报网4月3日讯，康希诺在接受调研者提问时表示，公司已建立起五大全面及完善的研发技术平台，未来公司的研发方向也包括利用已验证的技术平台持续开发新产品以及潜在创新平台的建立。mRNA平台是公司领先技术平台之一，公司正在进行mRNA治疗性疫苗的早期研发以及相关递送系统的开发。治疗领域方面，公司正在推进mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695225055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624668557","title":"康希诺：截至目前公司已递交了与婴幼儿用DTcP新药上市申请相关的加强针补充数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668557","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624668557?lang=zh_cn&edition=full","pubTime":"2026-04-03 21:28","pubTimestamp":1775222880,"startTime":"0","endTime":"0","summary":"证券日报网4月3日讯，康希诺在接受调研者提问时表示，截至目前，公司已递交了与婴幼儿用DTcP新药上市申请相关的加强针补充数据，持续推进上市申报进程，审批工作正在顺利推进中。相较于当前中国百白破疫苗市场主要使用的百日咳抗原共纯化DTaP疫苗，公司DTcP疫苗的每种百日咳抗原采用单独纯化技术，以确定的比例配制，从而确保质量稳定以及批次间一致性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695225494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624668555","title":"康希诺：截至2025年12月末母公司不存在未弥补亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668555","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624668555?lang=zh_cn&edition=full","pubTime":"2026-04-03 21:28","pubTimestamp":1775222880,"startTime":"0","endTime":"0","summary":"证券日报网4月3日讯，康希诺在接受调研者提问时表示，新《公司法》实施后，明确公司的公积金可用于弥补公司的亏损。为积极推动公司高质量发展，提升投资者回报能力和水平，2025年11月27日，公司召开第二次临时股东大会，审议通过《关于使用公积金弥补亏损的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695224839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624685376","title":"康希诺：根据2025年国内流行病学数据，脑膜炎球菌Y群在整体人群中发病率最高","url":"https://stock-news.laohu8.com/highlight/detail?id=2624685376","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624685376?lang=zh_cn&edition=full","pubTime":"2026-04-03 21:26","pubTimestamp":1775222760,"startTime":"0","endTime":"0","summary":"证券日报网4月3日讯，康希诺在接受调研者提问时表示，根据2025年国内流行病学数据，脑膜炎球菌Y群在整体人群中发病率最高，B群是仅次于Y群的第二大亚型，在婴幼儿年龄组的感染案例占比较高，且具有健康携带率高的特点，是常见的携带菌群之一，也是病菌社区传播的重要源头。目前国内尚未有B群脑膜炎疫苗获批上市，该医疗领域存在一定的市场空缺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695221882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779847070441,"stockEarnings":[{"period":"1week","weight":-0.0365},{"period":"1month","weight":-0.0487},{"period":"3month","weight":-0.0479},{"period":"6month","weight":-0.091},{"period":"1year","weight":0.0917},{"period":"ytd","weight":-0.0078}],"compareEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":0.016},{"period":"3month","weight":-0.0004},{"period":"6month","weight":0.0697},{"period":"1year","weight":0.2386},{"period":"ytd","weight":0.0445}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康希诺生物股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"16477人(较上一季度增加Infinity%)","perCapita":"6941股","listingDate":"2020-08-13","address":"天津市东丽区经济技术开发区西区南大街185号西区生物医药园四层401-420","registeredCapital":"24704万元","survey":" 康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是疫苗销售、药品生产工艺研究开发业务、技术转移及中间品销售。公司自主研发的“多糖蛋白结合疫苗关键技术及产业化”项目荣获天津市科学技术进步一等奖。","listedPrice":209.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺,688185,康希诺股票,康希诺股票老虎,康希诺股票老虎国际,康希诺行情,康希诺股票行情,康希诺股价,康希诺股市,康希诺股票价格,康希诺股票交易,康希诺股票购买,康希诺股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}